Regulation of endothelial homeostasis, vascular development and angiogenesis by the transcription factor ERG

Vascular Pharmacology

Volumn 86, Issue , 2016, Pages 3-13

  Shah, Aarti V ^a,b   Birdsey, Graeme M ^a   Randi, Anna M ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Angiogenesis; Endothelial homeostasis; ETS transcription factors; Gene transcription; Vascular development

Indexed keywords

BETA CATENIN; CLAUDIN 5; HISTONE DEACETYLASE 6; INTERCELLULAR ADHESION MOLECULE 2; NOTCH RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ERG; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; WNT PROTEIN; ERG PROTEIN, HUMAN;

ANGIOGENESIS; BINDING AFFINITY; BONE DEVELOPMENT; CARTILAGE; CELL MEMBRANE PERMEABILITY; DNA BINDING; ENDOTHELIUM; EWING SARCOMA; GENE; GENE STRUCTURE; GENE TARGETING; HEMATOPOIESIS; HOMEOSTASIS; HUMAN; LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; VASCULAR ENDOTHELIUM; VASCULAR TUMOR; VASCULITIS; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY;

ANIMALS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; TRANSCRIPTIONAL REGULATOR ERG;

EID: 84969931488     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2016.05.003     Document Type: Review

References (124)

1. [1] Adamo, P., Ladomery, M.R., The oncogene ERG: a key factor in prostate cancer. Oncogene, 2015, 10.1038/onc.2015.109 (Epub ahead of print).
2. [2] An, J., Ren, S., Murphy, S.J., Dalangood, S., Chang, C., Pang, X., et al. Truncated ERG oncoproteins from TMPRSS2-ERG fusions are resistant to SPOP-mediated proteasome degradation. Mol. Cell 59 (2015), 904–916.
3. [3] Anderson, M.K., Hernandez-Hoyos, G., Diamond, R.A., Rothenberg, E.V., Precise developmental regulation of ETS family transcription factors during specification and commitment to the T cell lineage. Development 126 (1999), 3131–3148.
4. [4] Baldus, C.D., Liyanarachchi, S., Mrózek, K., Auer, H., Tanner, S.M., Guimond, M., et al. Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: amplification discloses overexpression of APP, ETS2, and ERG genes. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 3915–3920.
5. [5] Baldus, C.D., Burmeister, T., Martus, P., Schwartz, S., Gökbuget, N., Bloomfield, C.D., et al. High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. J. Clin. Oncol. 24 (2006), 4714–4720.
6. [6] Baltzinger, M., Mager-Heckel, A.M., Remy, P., Xl Erg: expression pattern and overexpression during development plead for a role in endothelial cell differentiation. Dev. Dyn. 216 (1999), 420–433.
7. [7] Barr, F.G., Meyer, W.H., Role of fusion subtype in Ewing sarcoma. J. Clin. Oncol. 28 (2010), 1973–1974.
8. [8] Batta, K., Florkowska, M., Kouskoff, V., Lacaud, G., Direct reprogramming of murine fibroblasts to hematopoietic progenitor cells. Cell Rep. 9 (2014), 1871–1884.
9. [9] Bhasin, M., Yuan, L., Keskin, D.B., Otu, H.H., Libermann, T.A., Oettgen, P., Bioinformatic identification and characterization of human endothelial cell-restricted genes. BMC Genomics, 11, 2010, 342.
10. [10] Birdsey, G.M., Dryden, N.H., Amsellem, V., Gebhardt, F., Sahnan, K., Haskard, D.O., et al. Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood 111 (2008), 3498–3506.
11. [11] Birdsey, G.M., Dryden, N.H., Shah, A.V., Hannah, R., Hall, M.D., Haskard, D.O., et al. The transcription factor Erg regulates expression of histone deacetylase 6 and multiple pathways involved in endothelial cell migration and angiogenesis. Blood 119 (2012), 894–903.
12. [12] Birdsey, G.M., Shah, A.V., Dufton, N., Reynolds, L.E., Osuna Almagro, L., Yang, Y., et al. The endothelial transcription factor ERG promotes vascular stability and growth through Wnt/β-catenin signaling. Dev. Cell 32 (2015), 82–96.
13. [13] Brenner, J.C., Ateeq, B., Li, Y., Yocum, A.K., Cao, Q., Asangani, I.A., et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19 (2011), 664–678.
14. [14] Butticè, G., Duterque-Coquillaud, M., Basuyaux, J.P., Carrère, S., Kurkinen, M., Stéhelin, D., Erg, an ETS-family member, differentially regulates human collagenase1 (MMP1) and stromelysin1 (MMP3) gene expression by physically interacting with the Fos/Jun complex. Oncogene 13 (1996), 2297–2306.
15. [15] Camuzeaux, B., Spriet, C., Heliot, L., Coll, J., Duterque-Coquillaud, M., Imaging Erg and Jun transcription factor interaction in living cells using fluorescence resonance energy transfer analyses. Biochem. Biophys. Res. Commun. 332 (2005), 1107–1114.
16. [16] Carrere, S., Verger, A., Flourens, A., Stehelin, D., Duterque-Coquillaud, M., Erg proteins, transcription factors of the ETS family, form homo, heterodimers and ternary complexes via two distinct domains. Oncogene 16 (1998), 3261–3268.
17. [17] Cattelino, A., Liebner, S., Gallini, R., Zanetti, A., Balconi, G., Corsi, A., et al. The conditional inactivation of the beta-catenin gene in endothelial cells causes a defective vascular pattern and increased vascular fragility. J. Cell Biol. 162 (2003), 1111–1122.
18. [18] De Val, S., Chi, N.C., Meadows, S.M., Minovitsky, S., Anderson, J.P., Harris, I.S., et al. Combinatorial regulation of endothelial gene expression by ETS and forkhead transcription factors. Cell 135 (2008), 1053–1064.
19. [19] De Val, S., Black, B.L., Transcriptional control of endothelial cell development. Dev. Cell 16 (2009), 180–195.
20. [20] Dejana, E., The role of wnt signaling in physiological and pathological angiogenesis. Circ. Res. 107 (2010), 943–952.
21. [21] Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359 (1992), 162–165.
22. [22] Deramaudt, B.M., Remy, P., Abraham, N.G., Upregulation of human heme oxygenase gene expression by ETS-family proteins. J. Cell. Biochem. 72 (1999), 311–321.
23. [23] Dhordain, P., Dewitte, F., Desbiens, X., Stehelin, D., Duterque-Coquillaud, M., Mesodermal expression of the chicken Erg gene associated with precartilaginous condensation and cartilage differentiation. Mech. Dev. 50 (1995), 17–28.
24. [24] Dryden, N.H., Sperone, A., Martin-Almedina, S., Hannah, R.L., Birdsey, G.M., Khan, S.T., et al. The transcription factor Erg controls endothelial cell quiescence by repressing activity of nuclear factor (NF)-kappaB p65. J. Biol. Chem. 287 (2012), 12331–12342.
25. [25] Duterque-Coquillaud, M., Niel, C., Plaza, S., Stehelin, D., New human Erg isoforms generated by alternative splicing are transcriptional activators. Oncogene 8 (1993), 1865–1873.
26. [26] Ellett, F., Kile, B.T., Lieschke, G.J., The role of the ETS factor Erg in zebrafish vasculogenesis. Mech. Dev. 126 (2009), 220–229.
27. [27] Franco, C.A., Liebner, S., Gerhardt, H., Vascular morphogenesis: a Wnt for every vessel?. Curr. Opin. Genet. Dev. 19 (2009), 476–483.
28. [28] Franco, C.A., Blanc, J., Parlakian, A., Blanco, R., Aspalter, I.M., Kazakova, N., et al. SRF selectively controls tip cell invasive behavior in angiogenesis. Development 140 (2013), 2321–2333.
29. [29] Furusato, B., Tan, S.H., Young, D., Dobi, A., Sun, C., Mohamed, A.A., et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 13 (2010), 228–237.
30. [30] Gan, W., Dai, X., Lunardi, A., Li, Z., Inuzuka, H., Liu, P., et al. SPOP promotes ubiquitination and degradation of the ERG oncoprotein to suppress prostate cancer progression. Mol. Cell 59 (2015), 917–930.
31. [31] Ginsberg, M., James, D., Ding, B.S., Nolan, D., Geng, F., Butler, J.M., et al. Efficient direct reprogramming of mature amniotic cells into endothelial cells by ETS factors and TGFbeta suppression. Cell 151 (2012), 559–575.
32. [32] Gordanpour, A., Stanimirovic, A., Nam, R.K., Moreno, C.S., Sherman, C., Sugar, L., et al. miR-221 is down-regulated in TMPRSS2:ERG fusion-positive prostate cancer. Anticancer Res. 31 (2011), 403–410.
33. [33] Gory, S., Dalmon, J., Prandini, M.H., Kortulewski, T., de, L.Y., Huber, P., Requirement of a GT box (Sp1 site) and two ETS binding sites for vascular endothelial cadherin gene transcription. J. Biol. Chem. 273 (1998), 6750–6755.
34. [34] Han, R., Pacifici, M., Iwamoto, M., Trojanowska, M., Endothelial Erg expression is required for embryogenesis and vascular integrity. Organogenesis 11 (2015), 75–86.
35. [35] Hart, M., Wach, S., Nolte, E., Szczyrba, J., Menon, R., Taubert, H., et al. The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer. FEBS J. 280 (2013), 2105–2116.
36. [36] Hewett, P.W., Nishi, K., Daft, E.L., Clifford, M.J., Selective expression of Erg isoforms in human endothelial cells. Int. J. Biochem. Cell Biol. 33 (2001), 347–355.
37. [37] Hill, C.S., Marais, R., John, S., Wynne, J., Dalton, S., Treisman, R., Functional analysis of a growth factor-responsive transcription factor complex. Cell 73 (1993), 395–406.
38. [38] Hoesel, B., Malkani, N., Hochreiter, B., Basílio, J., Sughra, K., Ilyas, M., Schmid, J.A., Sequence-function correlations and dynamics of ERG isoforms. ERG8 is the black sheep of the family. Biochim. Biophys. Acta. 1863 (2016), 205–218.
39. [39] Hollenhorst, P.C., Jones, D.A., Graves, B.J., Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res. 32 (2004), 5693–5702.
40. [40] Hollenhorst, P.C., McIntosh, L.P., Graves, B.J., Genomic and biochemical insights into the specificity of ETS transcription factors. Annu. Rev. Biochem. 80 (2011), 437–471.
41. [41] Iwamoto, M., Higuchi, Y., Koyama, E., Enomoto-Iwamoto, M., Kurisu, K., Yeh, H., et al. Transcription factor ERG variants and functional diversification of chondrocytes during limb long bone development. J. Cell Biol. 150 (2000), 27–40.
42. [42] Iwamoto, M., Higuchi, Y., Enomoto-Iwamoto, M., Kurisu, K., Koyama, E., Yeh, H., et al. The role of ERG (ETS related gene) in cartilage development. Osteoarthr. Cartil. 9 (2001), 41–47.
43. [43] Iwamoto, M., Tamamura, Y., Koyama, E., Komori, T., Takeshita, N., Williams, J.A., et al. Transcription factor ERG and joint and articular cartilage formation during mouse limb and spine skeletogenesis. Dev. Biol. 305 (2007), 40–51.
44. [44] Jayaraman, G., Srinivas, R., Duggan, C., Ferreira, E., Swaminathan, S., Somasundaram, K., et al. p300/cAMP-responsive element-binding protein interactions with ETS-1 and ETS-2 in the transcriptional activation of the human stromelysin promoter. J. Biol. Chem. 274 (1999), 17342–17352.
45. [45] Kaluza, D., Kroll, J., Gesierich, S., Yao, T.P., Boon, R.A., Hergenreider, E., et al. Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactin. EMBO J. 30 (2011), 4142–4156.
46. [46] Kaur, S., Leszczynska, K., Abraham, S., Scarcia, M., Hiltbrunner, S., Marshall, C.J., et al. RhoJ/TCL regulates endothelial motility and tube formation and modulates actomyosin contractility and focal adhesion numbers. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 657–664.
47. [47] Khachigian, L.M., Fries, J.W., Benz, M.W., Bonthron, D.T., Collins, T., Novel cis-acting elements in the human platelet-derived growth factor B-chain core promoter that mediate gene expression in cultured vascular endothelial cells. J. Biol. Chem. 269 (1994), 22647–22656.
48. [48] Kim, J., Wu, L., Zhao, J.C., Jin, H.J., Yu, J., TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c. Oncogene 33 (2014), 5183–5192.
49. [49] Klambt, C., The Drosophila gene pointed encodes two ETS-like proteins which are involved in the development of the midline glial cells. Development 117 (1993), 163–176.
50. [50] Korn, C., Scholz, B., Hu, J., Srivastava, K., Wojtarowicz, J., Arnsperger, T., et al. Endothelial cell-derived non-canonical Wnt ligands control vascular pruning in angiogenesis. Development 141 (2014), 1757–1766.
51. [51] Lacronique, V., Boureux, A., Valle, V.D., Poirel, H., Quang, C.T., Mauchauffe, M., et al. A TEL–JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278 (1997), 1309–1312.
52. [52] Lathen, C., Zhang, Y., Chow, J., Singh, M., Lin, G., Nigam, V., et al. ERG-APLNR axis controls pulmonary venule endothelial proliferation in pulmonary veno-occlusive disease. Circulation 130 (2014), 1179–1191.
53. [53] Laumonnier, Y., Nadaud, S., Agrapart, M., Soubrier, F., Characterization of an upstream enhancer region in the promoter of the human endothelial nitric-oxide synthase gene. J. Biol. Chem. 275 (2000), 40732–40741.
54. [54] Le Bras, A., Samson, C., Trentini, M., Caetano, B., Lelievre, E., Mattot, V., et al. VE-statin/egfl7 expression in endothelial cells is regulated by a distal enhancer and a proximal promoter under the direct control of Erg and GATA-2. PLoS One, 5, 2010, e12156.
55. [55] Lelievre, E., Lionneton, F., Soncin, F., Vandenbunder, B., The ETS family contains transcriptional activators and repressors involved in angiogenesis. Int. J. Biochem. Cell Biol. 33 (2001), 391–407.
56. [56] Li, D., Xie, S., Ren, Y., Huo, L., Gao, J., Cui, D., et al. Microtubule-associated deacetylase HDAC6 promotes angiogenesis by regulating cell migration in an EB1-dependent manner. Protein Cell 2 (2011), 150–160.
57. [57] Liu, F., Patient, R., Genome-wide analysis of the zebrafish ETS family identifies three genes required for hemangioblast differentiation or angiogenesis. Circ. Res. 103 (2008), 1147–1154.
58. [58] Loughran, S.J., Kruse, E.A., Hacking, D.F., de Graaf, C.A., Hyland, C.D., Willson, T.A., et al. The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. Nat. Immunol. 9 (2008), 810–819.
59. [59] Mani, R.S., Iyer, M.K., Cao, Q., Brenner, J.C., Wang, L., Ghosh, A., et al. TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. Cancer Res. 71 (2011), 5387–5392.
60. [60] Marcucci, G., Maharry, K., Whitman, S.P., Vukosavljevic, T., Paschka, P., Langer, C., et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J. Clin. Oncol. 25 (2007), 3337–3343.
61. [61] McLaughlin, F., Ludbrook, V.J., Kola, I., Campbell, C.J., Randi, A.M., Characterisation of the tumour necrosis factor (TNF)-(alpha) response elements in the human ICAM-2 promoter. J. Cell Sci. 112 (1999), 4695–4703.
62. [62] McLaughlin, F., Ludbrook, V.J., Cox, J., von Carlowitz, I., Brown, S., Randi, A.M., Combined genomic and antisense analysis reveals that the transcription factor Erg is implicated in endothelial cell differentiation. Blood 98 (2001), 3332–3339.
63. [63] Meadows, S.M., Salanga, M.C., Krieg, P.A., Kruppel-like factor 2 cooperates with the ETS family protein ERG to activate Flk1 expression during vascular development. Development 136 (2009), 1115–1125.
64. [64] Miettinen, M., Wang, Z.F., Paetau, A., Tan, S.H., Dobi, A., Srivastava, S., et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am. J. Surg. Pathol. 35 (2011), 432–441.
65. [65] Mohamed, A.A., Tan, S.H., Mikhalkevich, N., Ponniah, S., Vasioukhin, V., Bieberich, C.J., et al. ETS family protein, Erg expression in developing and adult mouse tissues by a highly specific monoclonal antibody. J. Cancer 1 (2010), 197–208.
66. [66] Morita, R., Suzuki, M., Kasahara, H., Shimizu, N., Shichita, T., Sekiya, T., et al. ETS transcription factor ETV2 directly converts human fibroblasts into functional endothelial cells. Proc. Natl. Acad. Sci. 112 (2015), 160–165.
67. [67] Moulton, K.S., Semple, K., Wu, H., Glass, C.K., Cell-specific expression of the macrophage scavenger receptor gene is dependent on PU.1 and a composite AP-1/ETS motif. Mol. Cell. Biol. 14 (1994), 4408–4418.
68. [68] Murakami, K., Mavrothalassitis, G., Bhat, N.K., Fisher, R.J., Papas, T.S., Human ERG-2 protein is a phosphorylated DNA-binding protein—a distinct member of the ETS family. Oncogene 8 (1993), 1559–1566.
69. [69] Murakami, M., Nguyen, L.T., Hatanaka, K., Schachterle, W., Chen, P.Y., Zhuang, Z.W., Black, B.L., Simons, M., FGF-dependent regulation of VEGF receptor 2 expression in mice. J. Clin. Invest. 121 (2011), 2668–2678.
70. [70] Ng, A.P., Loughran, S.J., Metcalf, D., Hyland, C.D., de Graaf, C.A., Hu, Y., et al. ERG is required for self-renewal of hematopoietic stem cells during stress hematopoiesis in mice. Blood 118 (2011), 2454–2461.
71. [71] Nikolova-Krstevski, V., Yuan, L., Le, B.A., Vijayaraj, P., Kondo, M., Gebauer, I., et al. ERG is required for the differentiation of embryonic stem cells along the endothelial lineage. BMC Dev. Biol., 9, 2009, 72.
72. [72] Oikawa, T., Yamada, T., Molecular biology of the ETS family of transcription factors. Gene 303 (2003), 11–34.
73. [73] Owczarek, C.M., Portbury, K.J., Hardy, M.P., O'Leary, D.A., Kudoh, J., Shibuya, K., et al. Detailed mapping of the ERG–ETS2 interval of human chromosome 21 and comparison with the region of conserved synteny on mouse chromosome 16. Gene 324 (2004), 65–77.
74. [74] Peter, M., Mugneret, F., Aurias, A., Thomas, G., Magdelenat, H., Delattre, O., An EWS/ERG fusion with a truncated N-terminal domain of EWS in a Ewing's tumor. Int. J. Cancer 67 (1996), 339–342.
75. [75] Petrovic, N., Bhagwat, S.V., Ratzan, W.J., Ostrowski, M.C., Shapiro, L.H., CD13/APN transcription is induced by RAS/MAPK-mediated phosphorylationof Ets-2 in activated endothelial cells. J. Biol. Chem. 278 (2003), 49358–49368.
76. [76] Pimanda, J.E., Chan, W.Y., Donaldson, I.J., Bowen, M., Green, A.R., Gottgens, B., Endoglin expression in the endothelium is regulated by Fli-1, Erg, and Elf-1 acting on the promoter and a-8-kb enhancer. Blood 107 (2006), 4737–4745.
77. [77] Prasad, D.D., Rao, V.N., Lee, L., Reddy, E.S., Differentially spliced Erg-3 product functions as a transcriptional activator. Oncogene 9 (1994), 669–673.
78. [78] Rainis, L., Toki, T., Pimanda, J.E., Rosenthal, E., Machol, K., Strehl, S., et al. The proto-oncogene ERG in megakaryoblastic leukemias. Cancer Res. 65 (2005), 7596–7602.
79. [79] Randi, A.M., Sperone, A., Dryden, N.H., Birdsey, G.M., Regulation of angiogenesis by ETS transcription factors. Biochem. Soc. Trans. 37 (2009), 1248–1253.
80. [80] Rao, V.N., Papas, T.S., Reddy, E.S., Erg, a human ETS-related gene on chromosome 21: alternative splicing, polyadenylation, and translation. Science 237 (1987), 635–639.
81. [81] Rastogi, A., Tan, S.H., Mohamed, A.A., Chen, Y., Hu, Y., Petrovics, G., et al. Functional antagonism of TMPRSS2–ERG splice variants in prostate cancer. Genes Cancer 5 (2014), 273–284.
82. [82] Reddy, E.S., Rao, V.N., Erg, an ETS-related gene, codes for sequence-specific transcriptional activators. Oncogene 6 (1991), 2285–2289.
83. [83] Regan, M.C., Horanyi, P.S., Pryor, E.E. Jr., Sarver, J.L., Cafiso, D.S., Bushweller, J.H., Structural and dynamic studies of the transcription factor ERG reveal DNA binding is allosterically autoinhibited. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 13374–13379.
84. [84] Schachterle, W., Rojas, A., Xu, S.M., Black, B.L., ETS-dependent regulation of a distal Gata4 cardiac enhancer. Dev Biol. 361 (2012), 439–449.
85. [85] Schwachtgen, J.L., Janel, N., Barek, L., Duterque-Coquillaud, M., Ghysdael, J., Meyer, D., Kerbiriou-Nabias, D., Ets transcription factors bind and transactivate the core promoter of the von Willebrand factor gene. Oncogene 15 (1997), 3091–3102.
86. [86] Seidel, J.J., Graves, B.J., An ERK2 docking site in the pointed domain distinguishes a subset of ETS transcription factors. Genes Dev. 16 (2002), 127–137.
87. [87] Selvaraj, N., Kedage, V., Hollenhorst, P.C., Comparison of MAPK specificity across the ETS transcription factor family identifies a high-affinity ERK interaction required for ERG function in prostate cells. Cell Commun. Signal., 13, 2015, 12.
88. [88] Seth, A., Watson, D.K., ETS transcription factors and their emerging roles in human cancer. Eur. J. Cancer 41 (2005), 2462–2478.
89. [89] Sharrocks, A.D., The ETS-domain transcription factor family. Nat. Rev. Mol. Cell Biol. 2 (2001), 827–837.
90. [90] Shimizu, K., Ichikawa, H., Tojo, A., Kaneko, Y., Maseki, N., Hayashi, Y., et al. An ETS-related gene, ERG, is rearranged in human myeloid leukemia with t(16;21) chromosomal translocation. Proc. Natl. Acad. Sci. U. S. A. 90 (1993), 10280–10284.
91. [91] Shing, D.C., McMullan, D.J., Roberts, P., Smith, K., Chin, S.F., Nicholson, J., et al. FUS/ERG gene fusions in Ewing's tumors. Cancer Res. 63 (2003), 4568–4576.
92. [92] Siddique, H.R., Rao, V.N., Lee, L., Reddy, E.S., Characterization of the DNA binding and transcriptional activation domains of the Erg protein. Oncogene 8 (1993), 1751–1755.
93. [93] Singareddy, R., Semaan, L., Conley-Lacomb, M.K., St, J.J., Powell, K., Iyer, M., et al. Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2–ERG fusions. Mol. Cancer Res. 11 (2013), 1349–1361.
94. [94] Sorensen, P.H., Lessnick, S.L., Lopez-Terrada, D., Liu, X.F., Triche, T.J., Denny, C.T., A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat. Genet. 6 (1994), 146–151.
95. [95] Sperone, A., Dryden, N.H., Birdsey, G.M., Madden, L., Johns, M., Evans, P.C., et al. The transcription factor Erg inhibits vascular inflammation by repressing NF-kappaB activation and proinflammatory gene expression in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 142–150.
96. [96] Squire, J.A., TMPRSS2–ERG and PTEN loss in prostate cancer. Nat. Genet. 41 (2009), 509–510.
97. [97] Stamatovic, S.M., Keep, R.F., Mostarica-Stojkovic, M., Andjelkovic, A.V., CCL2 regulates angiogenesis via activation of ETS-1 transcription factor. J. Immunol. 177 (2006), 2651–2661.
98. [98] Sumanas, S., Lin, S., ETS1-related protein is a key regulator of vasculogenesis in zebrafish. PLoS Biol., 4, 2006, e10.
99. [99] Taoudi, S., Bee, T., Hilton, A., Knezevic, K., Scott, J., Willson, T.A., et al. ERG dependence distinguishes developmental control of hematopoietic stem cell maintenance from hematopoietic specification. Genes Dev. 25 (2011), 251–262.
100. [100] Thoms, J.A., Birger, Y., Foster, S., Knezevic, K., Kirschenbaum, Y., Chandrakanthan, V., et al. ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer. Blood 117 (2011), 7079–7089.
101. [101] Tomlins, S.A., Laxman, B., Varambally, S., Cao, X., Yu, J., Helgeson, B.E., et al. Role of the TMPRSS2–ERG gene fusion in prostate cancer. Neoplasia 10 (2008), 177–188.
102. [102] Tomlins, S.A., Rhodes, D.R., Perner, S., Dhanasekaran, S.M., Mehra, R., Sun, X.W., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005), 644–648.
103. [103] Verger, A., Buisine, E., Carrere, S., Wintjens, R., Flourens, A., Coll, J., et al. Identification of amino acid residues in the ETS transcription factor Erg that mediate Erg-Jun/Fos-DNA ternary complex formation. J. Biol. Chem. 276 (2001), 17181–17189.
104. [104] Vijayaraj, P., Le, B.A., Mitchell, N., Kondo, M., Juliao, S., Wasserman, M., et al. Erg is a crucial regulator of endocardial–mesenchymal transformation during cardiac valve morphogenesis. Development 139 (2012), 3973–3985.
105. [105] Vlaeminck-Guillem, V., Carrere, S., Dewitte, F., Stehelin, D., Desbiens, X., Duterque-Coquillaud, M., The ETS family member Erg gene is expressed in mesodermal tissues and neural crests at fundamental steps during mouse embryogenesis. Mech. Dev. 91 (2000), 331–335.
106. [106] Vlaeminck-Guillem, V., Vanacker, J., Verger, A., Tomavo, N., Stehelin, D., Laudet, V., et al. Mutual repression of transcriptional activation between the ETS-related factor ERG and estrogen receptor. Oncogene 22 (2003), 8072–8084.
107. [107] Wakiya, K., Begue, A., Stehelin, D., Shibuya, M., A cAMP response element and an ETS motif are involved in the transcriptional regulation of flt-1 tyrosine kinase (vascular endothelial growth factor receptor 1) gene. J. Biol. Chem. 271 (1996), 30823–30828.
108. [108] Wareing, S., Mazan, A., Pearson, S., Göttgens, B., Lacaud, G., Kouskoff, V., The Flk1-Cre-mediated deletion of ETV2 defines its narrow temporal requirement during embryonic hematopoietic development. Stem Cells 30 (2012), 1521–1531.
109. [109] Wang, L.C., Kuo, F., Fujiwara, Y., Gilliland, D.G., Golub, T.R., Orkin, S.H., Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the ETS-related factor TEL. EMBO J. 16 (1997), 4374–4383.
110. [110] Wang, J., Cai, Y., Yu, W., Ren, C., Spencer, D.M., Ittmann, M., Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res. 68 (2008), 8516–8524.
111. [111] Wang, S., Kollipara, R.K., Srivastava, N., Li, R., Ravindranathan, P., Hernandez, E., et al. Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 4251–4256.
112. [112] Wei, G., Srinivasan, R., Cantemir-Stone, C.Z., Sharma, S.M., Santhanam, R., Weinstein, M., et al. ETS1 and ETS2 are required for endothelial cell survival during embryonic angiogenesis. Blood 114 (2009), 1123–1130.
113. [113] Wei, G.H., Badis, G., Berger, M.F., Kivioja, T., Palin, K., Enge, M., et al. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J. 29 (2010), 2147–2160.
114. [114] Wernert, N., Raes, M.B., Lassalle, P., Dehouck, M.P., Gosselin, B., Vandenbunder, B., et al. c-ETS1 proto-oncogene is a transcription factor expressed in endothelial cells during tumor vascularization and other forms of angiogenesis in humans. Am. J. Pathol. 140 (1992), 119–127.
115. [115] Wilson, N.K., Foster, S.D., Wang, X., Knezevic, K., Schutte, J., Kaimakis, P., et al. Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. Cell Stem Cell 7 (2010), 532–544.
116. [116] Wythe, J.D., Dang, L.T., Devine, W.P., Boudreau, E., Artap, S.T., He, D., et al. ETS factors regulate Vegf-dependent arterial specification. Dev. Cell 26 (2013), 45–58.
117. [117] Yang, L., Xia, L., Wu, D.Y., Wang, H., Chansky, H.A., Schubach, W.H., et al. Molecular cloning of ESET, a novel histone H3-specific methyltransferase that interacts with ERG transcription factor. Oncogene 21 (2002), 148–152.
118. [118] Yang, L., Mei, Q., Zielinska-Kwiatkowska, A., Matsui, Y., Blackburn, M.L., Benedetti, D., et al. An ERG (ETS-related gene)-associated histone methyltransferase interacts with histone deacetylases 1/2 and transcription co-repressors mSin3A/B. Biochem. J. 369 (2003), 651–657.
119. [119] Yu, J., Yu, J., Mani, R.S., Cao, Q., Brenner, C.J., Cao, X., et al. An integrated network of androgen receptor, polycomb, and TMPRSS2–ERG gene fusions in prostate cancer progression. Cancer Cell 17 (2010), 443–454.
120. [120] Yuan, L., Nikolova-Krstevski, V., Zhan, Y., Kondo, M., Bhasin, M., Varghese, L., et al. Antiinflammatory effects of the ETS factor ERG in endothelial cells are mediated through transcriptional repression of the interleukin-8 gene. Circ. Res. 104 (2009), 1049–1057.
121. [121] Yuan, L., Sacharidou, A., Stratman, A.N., Le, B.A., Zwiers, P.J., Spokes, K., et al. RhoJ is an endothelial cell-restricted Rho GTPase that mediates vascular morphogenesis and is regulated by the transcription factor ERG. Blood 118 (2011), 1145–1153.
122. [122] Yuan, L., Le, B.A., Sacharidou, A., Itagaki, K., Zhan, Y., Kondo, M., et al. ETS-related gene (ERG) controls endothelial cell permeability via transcriptional regulation of the claudin 5 (CLDN5) gene. J. Biol. Chem. 287 (2012), 6582–6591.
123. [123] Zammarchi, F., Boutsalis, G., Cartegni, L., 5′ UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer. PLoS One, 8, 2013, e49721.
124. [124] Zheng, H., Wasylyk, C., Ayadi, A., Abecassis, J., Schalken, J.A., Rogatsch, H., et al. The transcription factor Net regulates the angiogenic switch. Genes Dev. 17 (2003), 2283–2297.